T1	Participants 371 403	postmenopausal, osteopenic women
T2	Participants 405 430	Women aged 50 to 80 years
T3	Participants 501 630	raloxifene (group 1, n=20) or placebo (group 2, n=20) for a further 96 weeks. A third group (group 3, n=14) received no treatment
